Granulocytic differentiation of leukemic cells with t(9;11)(p22;q23) induced by all-trans-retinoic acid.

Abstract

Acute leukemia patients with MLL (mixed linage leukemia) rearrangements tend to respond poorly to conventional therapies. We examined differentiation of human myeloid leukemia cells displaying the MLL-AF9 gene, using several differentiation agents. When MOLM-14 cells were treated with all-trans retinoic acid (ATRA) or 1beta,25-dihydroxyvitamin D3, significant induced differentiation was observed. Trichostatin A (TSA), an inhibitor of histone deacetylase, demonstrated enhance effects with ATRA in regard to growth inhibition and differentiation induction in MOLM-14 cells. Pretreatment with TSA before exposure to ATRA displayed increased effect. Based on these findings, combined treatment with ATRA and TSA may be clinically useful in therapy for acute leukemia displaying MLL-AF9 fusion gene.

• Authors: Kimiko Iijima, Yoshio Honma, Nozomi Niitsu
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 45 Issue 5 Pg. 1017-24 (May 2004) ISSN: 1042-8194 [Print] United States
• PMID: 15291362 (Publication Type: Journal Article)

Chemical References

• CDKN1A protein, human
• Cell Cycle Proteins
• Cyclin-Dependent Kinase Inhibitor p21
• Hydroxamic Acids
• RARA protein, human
• Receptors, Retinoic Acid
• Retinoic Acid Receptor alpha
• trichostatin A
• Tretinoin

Topics

• Acute Disease
• Cell Cycle Proteins (genetics)
• Cell Differentiation (drug effects)
• Cell Line, Tumor
• Chromosomes, Human, Pair 11
• Chromosomes, Human, Pair 9
• Cyclin-Dependent Kinase Inhibitor p21
• Drug Synergism
• Granulocytes (drug effects, pathology)
• Humans
• Hydroxamic Acids (pharmacology)
• Leukemia, Myeloid (drug therapy, genetics, pathology)
• Receptors, Retinoic Acid (genetics)
• Retinoic Acid Receptor alpha
• Translocation, Genetic
• Tretinoin (pharmacology)
• Up-Regulation (drug effects)